Robbie McLaren

  • 99 Bishopsgate
  • London EC2M 3XF
  • United Kingdom

Robbie McLaren is a partner in the London office of Latham & Watkins and Co-Chair of the London Corporate Department. His practice focuses primarily on cross-border M&A, joint ventures, venture capital, reorganizations, and general corporate matters. Mr. McLaren has represented clients who operate in a number of industries, with a particular focus on clients in the life sciences, healthcare, and technology industries.


Mr. McLaren's representative experience includes advising:

Life Sciences and Healthcare

  • Baxter International Inc., in connection with its US$625 million acquisition of Claris Injectables Limited, an India-based manufacturer of sterile injectables 
  • Sienna Biopharmaceuticals in connection with its acquisition of Creabilis plc, a privately held specialty pharmaceutical company
  • Allergan on its US$40.5 billion sale of its global generics pharmaceuticals business to Teva
  • Certain investors on their financings of Entasis Therapeutics, Meira GTx, and Adaptimmune
  • The shareholders of Pharmathen SA, a Greek pharmaceuticals company, on their sale of a controlling interest in Pharmathen to BC Partners
  • Actavis on its £306 million acquisition of Auden Mckenzie, a pharmaceutical company specializing in the development, licensing, and marketing of generic medicines and proprietary brands
  • Zogenix on its acquisition of Brabant Pharma, a UK-based pharmaceutical company
  • Actavis on the divestment of part of its Western European generics sale and marketing business to Aurobindo
  • Novo A/S on its £230 million disposal of Archimedes and its US$706 million acquisition of Xellia
  • Watson Pharmaceuticals on its €4.25 billion acquisition of the Actavis Group, making Watson the third largest global generics company
  • Theramex, a global specialty pharmaceutical company dedicated to women’s healthcare, in connection with the US$703 million acquisition by CVC Capital Partners of women’s healthcare assets from Teva Pharmaceutical Industries Ltd.

Technology, Media, and Telecoms

  • Kite Tech, a UK-based mobile e-commerce platform specializing in personalized print on its sale to Canon Europa
  • Netlix Inc. on the acquisition of Millarworld, a comic book company founded by Mark Millar
  • An Asian investor in connection with its investment in a major music and audio platform
  • Andreessen Horowitz on its minority investment in Improbable World Limited, a UK-based software developer focused on virtual and simulated worlds 
  • Great Hill Partners on their acquisition of Momondo and its disposal for US$550 million to Priceline 
  • Intapp on their acquisition of Rekoop
  • The Carlyle Group on its US$400 million investment in Ion Trading and its US$700 million acquisition of Dealogic
  • BluWrap on various equity financings
  • Calysta on their acquisition of BioProtein A/S


  • Mubadala on the US$15 billion merger of EMAL and DUBAL to form Emirates Global Aluminum
  • Amphenol Corp on its US$1.28 billion acquisition of FCI Asia, a provider of interconnect solutions for the telecom, datacom, wireless communications, and industrial markets owned by Bain Capital
  • Coesia SpA in connection with the acquisition by G.D, a wholly owned subsidiary of Coesia, of the Instrumentation & Tobacco Machinery business of Molins, a manufacturer of secondary tobacco processing machinery
  • Solway Investment Group in connection with its sale of Rudnik SASA Makedonska Kamenica, a Macedonia-based mining field engaged in production of lead-zinc metal, to Orion Mine Finance Group and Fusion Capital
  • Ma’aden on its acquisition of a 50% interest in the Jabal Sayid copper and gold project in Saudi Arabia from Barrick Gold Corporation
  • Global Alumina Inc. on the sale of its 33% interest in a bauxite and alumina project in Guinea to Mubadala
  • Norsk Hydro ASA on its US$5.27 billion acquisition of the majority of the aluminium business of Vale SA in Brazil
Notice: We appreciate your interest in Latham & Watkins. If your inquiry relates to a legal matter and you are not already a current client of the firm, please do not transmit any confidential information to us. Before taking on a representation, we must determine whether we are in a position to assist you and agree on the terms and conditions of engagement with you. Until we have completed such steps, we will not be deemed to have a lawyer-client relationship with you, and will have no duty to keep confidential the information we receive from you. Thank you for your understanding.